Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kelly Garrett
Institutions:
NewYork–Presbyterian Hospital,
Cornell University,
Weill Cornell Medicine
Observed institutions:
NewYork–Presbyterian Hospital,
Cornell University,
Weill Cornell Medicine
ORCID:
0000-0001-9636-8288
Observed ORCID:
0000-0001-9636-8288
OpenAlex ID:
A5134236140
Caspase 5c amplifies Wnt via APC cleavage to promote intestinal homeostasis
2026
·
Baosen Jia
, Yuhua Shi
, et al.
·
Nature
·
5
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
2026
·
Hui-Hsuan Kuo
, Bhavneet Bhinder
, et al.
·
Science Advances
·
3
PDF
Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
·
Clinical Cancer Research
·
1
Supplementary Figure S7 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 4 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S13 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S9 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S7 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S12 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Table 1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S6 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Figure 5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S14 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Table S1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S1 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Data from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Supplementary Figure S10 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
2026
·
Manish A. Shah
, Erika Hissong
, et al.
Show more works
View as search
Works count:
32
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type